歌禮製藥(01672.HK)終止研發HIV候選藥物ASC09
歌禮製藥(01672.HK)宣布終止旗下HIV蛋白(酉每)抑制劑候選藥物ASC09的研究開發,公司曾開發用於治療HIV 1型感染,但由於相關替代產品已在中國推出及上市,並成為治療HIV 1型感染的主流,因此預期ASC09可能沒有競爭優勢,決定終止相關研發,目前正在終止過程中。公司計劃重新分配資源至其他 管線產品及新產品研發以把握未來市場機遇。
公司透露,旗下用於慢性乙肝功能性治癒的免疫療法ASC22、口服雙前藥ASC10及新冠肺炎口服候選藥物蛋白(酉每)抑制劑ASC11,均可能於未來三年內啟動商業化。(gc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.